[October 2, 2013 John Reynolds Re: China Cord Blood Corporation Registration Statement on Form F-3 Filed September 12, 2013 File No. 333-191121 Dear Mr. Reynolds: We hereby provide responses to comments issued on September 26, 2013 (the “Staff’s Letter”) regarding the Registration Statement on Form F-3 (File No. 333-191121)(the “F-3”) of China Cord Blood Corporation (the “Company”). In order to]
[October 2, 2013 John Reynolds Re: China Cord Blood Corporation Registration Statement on Form F-3 Filed September 12, 2013 File No. 333-191121 Dear Mr. Reynolds: We hereby provide responses to comments issued on September 26, 2013 (the “Staff’s Letter”) regarding the Registration Statement on Form F-3 (File No. 333-191121)(the “F-3”) of China Cord Blood Corporation (the “Company”). In order to]
[21VIANET ANNOUNCES US$100 MILLION INVESTMENT FROM TEMASEK BEIJING We welcome Temaseks investment in our Company and believe that its deep expertise in Asias telecom industry will significantly benefit 21Vianet going forward, said Mr. Josh Chen, co-founder, chairman and chief executive officer of 21Vianet. With this investment from one of the most reputable investment companies in Asia, 21Vianet can better leverage] [FORM 6-K 21Vianet Group, Inc. M5, 1 Jiuxianqiao East Road, Chaoyang District Beijing 100016 The Peoples Republic of China (86 10) 8456 2121 x ¨ Form 20-F ¨ ¨ 21Vianet Group, Inc. Shang-Wen Hsiao Chief Financial Officer 6-K 1 d608402d6k.htm FORM 6-K]
[TPI Announces Fiscal Year 2013 Financial Results September 27, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2013. Fiscal Year 2013 Ended June 30, 2013 Financial Highlights: · Revenue was $67.5 million compared] [Tianyin Pharmaceutical Inc. Fiscal Year 2013 Annual Financial Results Conference Call September 27, 2013 Operator James Tong - Chief Financial Officer. Financial highlights of Fiscal year 2013 ended June 30, 2013: Revenue totaled $67.5 million compared with $69.6 million in fiscal year 2012, a decrease of 3% year-over-year. Operating income was $9.3 million, compared with $8.5 million in fiscal year] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 27, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[TPI Announces Fiscal Year 2013 Financial Results September 27, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2013. Fiscal Year 2013 Ended June 30, 2013 Financial Highlights: · Revenue was $67.5 million compared] [Tianyin Pharmaceutical Inc. Fiscal Year 2013 Annual Financial Results Conference Call September 27, 2013 Operator James Tong - Chief Financial Officer. Financial highlights of Fiscal year 2013 ended June 30, 2013: Revenue totaled $67.5 million compared with $69.6 million in fiscal year 2012, a decrease of 3% year-over-year. Operating income was $9.3 million, compared with $8.5 million in fiscal year] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 27, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[October 2, 2013 John Reynolds Re: Chinard Bloodrporation Registration Statement on Form F-3 Filed September 12, 2013 File No. 333-191121 Dear Mr. Reynolds: We hereby provide responses tomments issued on September 26, 2013 (the Staffs Letter) regarding the Registration Statement on Form F-3 (File No. 333-191121)(the F-3) of Chinard Bloodrporation (thempany).]
[October 2, 2013 John Reynolds Re: Chinard Bloodrporation Registration Statement on Form F-3 Filed September 12, 2013 File No. 333-191121 Dear Mr. Reynolds: We hereby provide responses tomments issued on September 26, 2013 (the Staffs Letter) regarding the Registration Statement on Form F-3 (File No. 333-191121)(the F-3) of Chinard Bloodrporation (thempany).]
[General Steel Receives Notice Regarding NYSE Listing Criteria Under NYSE rules, the Company has 45 days from the date of the notice to submit a plan to the NYSE demonstrating its ability to achieve compliance with the continued listing standards within 18 months of receiving the notice. The Company intends to submit such plan and has notified the NYSE that] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): September 26, 2013 General Steel Holdings, Inc. Nevada 001-33717 41-2079252 (State or other jurisdiction (IRS Employer of incorporation) Identification Number) Level 21, Tower B, Jia Ming Center No. 27 Dong San Huan North Road Chaoyang District, Beijing, China 100020 + 86 (10) 57757691 (Former name or former address,]
